

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

TERMINATION OF CONTINUING CONNECTED TRANSACTIONS

This announcement is made by Sinopharm Tech Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 20.33 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”).

Reference is made to the announcement of the Company dated 5 July 2021 (the “**Announcement**”) in relation to the continuing connected transactions of the Licensing and Master Service Agreement in relation to the provision of the Total Solutions on anti-counterfeiting device product. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Company has received a notice from the Licensor informing the Company to terminate the Licensing and Master Service Agreement with effect from 13 January 2023, pursuant to which the Licensing and Master Service Agreement may be terminated at any time by either party upon three months’ prior written notice to the other party. There was no transaction for the year ended 30 June 2022 and up to the date of this announcement. The Board is of the view that the termination of the transactions contemplated under the Licensing and Master Service Agreement will not have any material adverse effect on the financial position and business operations of the Group.

The Group will continue to focus on and step up its efforts to develop its “Internet Plus” services on supply chain business. According to the service agreement entered into by the Group with a platform operator in Mainland China and the supply chain service agreement entered into by the Group with a retail and gift redemption chain store for one-stop professional photographic equipment and electronic digital products in Macau, pursuant to both of which the Group will provide “Internet Plus” supply chain services to the affiliated companies of the platform operators; and real-time product delivery and procurement services to the retail and gift redemption chain store respectively. The Group is fully engaged in all these related businesses.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAU Wai Wah Fred
Executive Director

Hong Kong, 21 October 2022

As at the date of this announcement, the Board comprises Mr. CHAU Wai Wah Fred, Mr. HO Kam Kin and Ms. KWOK Shuk Yi as executive Directors, Dr. CHENG Yanjie as non-executive Director and Mr. LAU Fai Lawrence, Dr. LIU Ta-pei and Mr. LAM Kit Sun as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkexnews.hk for a minimum period of 7 days from the date of its publication and on the website of the Company at www.sinopharmtech.com.hk.